cbmtg 0801 moving forward …
DESCRIPTION
CBMTG 0801 Moving Forward …. Activation Timeline. Canadian Sites. Projected Accrual. Site Activation. IRB approval Regulatory Documents (Checklist) Centre criteria for myeloablative and RIC HPCT SOP for transplant decision Site Agreement signed Site Initiation (Web conference). Consent. - PowerPoint PPT PresentationTRANSCRIPT
CBMTG 0801Moving Forward …
Activation Timeline
Canadian Sites
Projected Accrual
Site Activation
• IRB approval
• Regulatory Documents (Checklist)Centre criteria for myeloablative and RIC HPCTSOP for transplant decision
• Site Agreement signed
• Site Initiation (Web conference)
Consent
• Within 60 days of transplant
• French and English templates
• Verbal translation -- if ok with local REB
Thymoglobulin in Unrelated Transplant
CBMTG 0801
If you will be undergoing a transplant from an unrelated donor for blood cancer, then you may be eligible for this trial.
This trial involves the addition of a drug called Thymoglobulin to the conditioning regimen prior to transplant.
Screening Period
• Day -60 to Day -8
• Study procedures – standard work-up (except for study questionnaires)
• Health Canada guidelines for IDM’s
• Questionnaires to be completed prior to start of conditioning
Randomization• All I & E must be met
• Randomize no earlier than 14 days prior to start of the preparative regimen
• Can be randomized up until 1 day prior to start of preparative
• Fax or email pdf to: Data Management Office (Vancouver)
Study Procedures – Post HPCT
Immune Reconstitution
QOL, Chronic GVHD Follow-Up & HE
Project Website
http://cbmtg0801.org
Study Tools
• Procedures spreadsheet
• Participant Information Pamphlet (in development)
• Days post transplant calculator
Study Schedule
Data Collection
• Case report form posted on website (soon)
• Forms due within 1 month of time point
• Data locks q 6 months
AE/SAE Reporting• AE’s grade 3 or greater to day 30
• CTCAE version 3.0
• Day 31 to 24 months – SAE’s only
• Report to DM Office within 24 hours (DM will report to Health Canada and
Genzyme)
• DSMC meets twice/year and as needed
Infections• All grade 4 and 5 infections will be recorded in
the Data Collection Forms (and reported as SAEs)
• Additional information:Type of organism (suspected or documented); Activation of CMV requiring treatmentActivation of EBV either with symptoms or requiring
treatmentPrimary organ involved
Centre Funding
• CENTRE FUNDING (CIHR) Per Patient Entered: $4000
• THYMOGLOBULIN: Order by centre, reimburse ($3900 per patient )
• SITE START-UP: $2,000 per site Pharmacy, preparation of IRB submission, etc.
Site Agreements
• Caroline Woods at McMaster University
• They will be sent to the PI, contracts office and study coordinator
• Coming soon …
Questions?